PMID- 12435204
OWN - NLM
STAT- MEDLINE
DCOM- 20040402
LR  - 20151119
IS  - 0890-9091 (Print)
IS  - 0890-9091 (Linking)
VI  - 16
IP  - 10
DP  - 2002 Oct
TI  - HER2 testing and correlation with efficacy of trastuzumab therapy.
PG  - 1340-8, 1351-2; discussion 1352, 1355-8
AB  - The need for accurate detection of HER2 status is becoming more apparent, as 
      therapeutic decisions are influenced by this information in both the adjuvant and 
      advanced-stage setting. Since the US Food and Drug Administration approved 
      trastuzumab (Herceptin) for the treatment of metastatic breast cancer, the 
      urgency of accurately evaluating HER2 status of breast cancer specimens, in order 
      to identify patients who might benefit from this therapy, has increased. A wide 
      range of assay methods are available for determining HER2 status, but 
      immunohistochemistry followed by fluorescence in situ hybridization (FISH) is the 
      recommended approach for ambiguous cases. FISH is not as widely available and is 
      more costly than immunohistochemistry, but economic modeling shows that it is the 
      most effective (and cost-effective) option.
FAU - Fornier, Monica
AU  - Fornier M
AD  - Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, 
      New York 10021, USA.
FAU - Risio, Mauro
AU  - Risio M
FAU - Van Poznak, Catherine
AU  - Van Poznak C
FAU - Seidman, Andrew
AU  - Seidman A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Oncology (Williston Park)
JT  - Oncology (Williston Park, N.Y.)
JID - 8712059
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
CIN - Oncology (Williston Park). 2002 Nov;16(11):1576, 1578. PMID: 12469932
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*therapeutic use
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*chemistry/*drug therapy
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Receptor, ErbB-2/*analysis
MH  - Trastuzumab
RF  - 59
EDAT- 2002/11/19 04:00
MHDA- 2004/04/03 05:00
CRDT- 2002/11/19 04:00
PHST- 2002/11/19 04:00 [pubmed]
PHST- 2004/04/03 05:00 [medline]
PHST- 2002/11/19 04:00 [entrez]
AID - 172068 [pii]
PST - ppublish
SO  - Oncology (Williston Park). 2002 Oct;16(10):1340-8, 1351-2; discussion 1352, 
      1355-8.